National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Invizyne is a biotechnology company focused on revolutionizing biomanufacturing through the development of innovative enzyme-based systems. The company specializes in designing enzymes and constructing cell-free enzymatic pathways that operate continuously and independently outside of living cells. This approach addresses many challenges associated with traditional cell-based biomanufacturing technologies. Invizyne's flagship platform, SimplePath, aims to efficiently convert natural and renewable resources into a variety of valuable chemicals, including pharmaceuticals, fuels, materials, and food additives. By providing a modular and cascading system, Invizyne seeks to offer a viable alternative to conventional methods of chemical production, such as chemical synthesis and natural extraction, thereby enhancing the efficiency and sustainability of the biomanufacturing process.

GreenMark Biomedical Inc. is a minimally invasive healthcare company focused on developing innovative technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company specializes in dental and medical applications. Its dental technologies include a mouth rinse product that illuminates cavities and early-stage lesions, allowing dentists to accurately diagnose and treat tooth decay. Additionally, GreenMark's medical technologies are designed for targeted delivery of anti-cancer drugs, enhancing treatment precision. The company aims to provide health benefits through its advanced nanoparticle-based solutions, promoting less invasive and more effective healthcare practices.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company specializes in harnessing molecular machines that convert energy into mechanical work within cells. This technology enables targeted treatment of various disease states, including cancer, by focusing on cellular motor proteins. Through its research and development efforts, Myosin Therapeutics aims to address critical challenges in disease management and improve patient outcomes.

Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Rhealth is a biotechnology company that specializes in health management solutions by leveraging advanced artificial intelligence. It offers a platform designed for hospitals, facilitating the delivery of comprehensive health information to both physicians and patients. The company's innovative technologies transform the accessibility of analytical and diagnostic information, integrating portable diagnostic and monitoring capabilities. This enables healthcare providers to offer improved and timely health information, ultimately enhancing patient care.

BMI OrganBank is a company that specializes in the development of innovative medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve outcomes for patients in need. BMI OrganBank is particularly focused on transforming kidney transplantation and advancing organ preservation methods, with the goal of benefiting thousands of patients awaiting transplants. Additionally, the company is involved in creating technologies such as lung ventilators and ex vivo tissue perfusion systems, which are designed to enable healthcare providers to deliver improved medical care.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm specializes in creating unique and transformative medicines that specifically target brain-related conditions. Sparian is committed to advancing therapeutic solutions that address both acute and chronic pain through cutting-edge science and novel drug discovery methods.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for pain management. The company addresses significant unmet needs in both chronic and acute pain treatment, moving beyond traditional systemic approaches. Its flagship product, Neural Ice™, is a drug-free injectable therapy designed to provide safe and effective pain relief through reversible inhibition of nerve activity. This novel solution offers patients a long-lasting relief period, with effectiveness extending from thirty to sixty days following a single injection. By prioritizing non-addictive and locally targeted therapies, Brixton Biosciences aims to transform pain management practices and improve the quality of life for patients suffering from various forms of pain.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Teal Health is dedicated to improving women's health by providing innovative solutions, starting with at-home cervical cancer screenings. The company has developed the first FDA-approved device that allows women to perform cervical cancer screenings in the comfort and privacy of their own homes. By simplifying the screening process, Teal Health aims to encourage timely screenings and promote early treatment, ultimately working towards the eradication of cervical cancer in the United States. The company's mission focuses on designing health solutions that cater to women's preferences and experiences, addressing the pressing issues in women's health with a commitment to empowerment and accessibility.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

CytoAgents, Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing innovative protein-based drugs aimed at treating viral infectious diseases, particularly focusing on life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an inflammatory response characterized by an overactive immune system, often linked to conditions such as oncology CAR-T cell therapy and COVID-19. CytoAgents' lead product, GP1681, acts as an agonist of a G-protein coupled receptor and represents a novel therapeutic approach to manage the immune response in patients experiencing cytokine storms. Through its research and development efforts, CytoAgents aims to address significant unmet medical needs across various indications, enhancing treatment efficacy for patients suffering from severe systemic inflammation.

Resvita Bio is a biotechnology company focused on developing and manufacturing engineered probiotics specifically designed to treat various skin-related diseases, including cancer. The company utilizes synthetic biology and metabolic engineering to create a versatile skin microbial platform. This platform aims to deliver therapies that reduce inflammation, repair damaged tissue, and eliminate harmful bacteria, offering faster and more effective treatment options for chronic skin conditions.

Cenna Biosciences is a biosciences company focused on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company employs a proprietary mechanism to address the underlying cause of the disease, specifically targeting the inappropriate deposition of toxic ß-amyloid species in the brains of affected patients. Cenna Biosciences has identified a novel target and is actively developing several lead peptide compounds as disease-modifying candidates for Alzheimer's treatment.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Evoq Therapeutics is a cancer immunotherapy company focused on developing disease-specific immune modulators aimed at treating patients with autoimmune diseases. The company employs a novel, proprietary technology platform based on NanoDisc, which is designed to deliver antigens effectively and restore immune tolerance. This innovative approach has demonstrated efficacy in multiple preclinical models, addressing conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By harnessing the body's natural immune tolerance pathways, Evoq Therapeutics aims to improve the quality of life for individuals battling these challenging autoimmune disorders.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Unlocked Labs specializes in the development of genetically optimized probiotics aimed at addressing chronic health conditions. The company focuses on activating dormant microbial abilities within a safe and established framework. Its rigorously tested probiotic strains are specifically designed to target and eliminate harmful compounds in the gastrointestinal tract. Unlocked Labs' inaugural product is formulated to reduce the risk of kidney stones by digesting stone-forming compounds that may be ingested from healthy foods, such as leafy vegetables. By utilizing alternative regulatory pathways, the company seeks to expedite the availability of safe and effective probiotic solutions for consumers, enabling them to detoxify their bodies and manage acid levels affordably and effectively.

Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. It develops and commercializes innovative diagnostic tools using its proprietary technology platform, IMMray, which is based on antibody microarray analysis. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests. By collaborating with medical institutions and research centers worldwide, Immunovia aims to bring its diagnostic solutions to market, significantly impacting the treatment and management of pancreatic cancer and potentially improving survival rates. Its approach to utilizing blood-based biomarkers may also enable early detection strategies for other cancers and autoimmune diseases.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials indicate that ANEB-001 is quickly absorbed and well-tolerated, with additional benefits such as weight loss, which aligns with its action as a central cannabinoid receptor type 1 antagonist. The company aims to address a significant medical need, as symptoms of cannabinoid overdose can vary widely, including severe sedation, anxiety, panic, and psychotic episodes with hallucinations.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, the company specializes in developing bioresorbable smart polymers specifically designed for vascular surgery. Its flagship product, SelfWrap, is a perivascular wrap that functions as an external stent to enhance the success of dialysis procedures. SelfWrap addresses complications at the vein-artery or vein-graft junction by promoting outward vein growth and providing customized mechanical support, thereby reducing the risk of vein collapse and occlusion. This innovative approach utilizes a new class of shape-memory polymers that do not require sutures, ultimately improving surgical outcomes, reducing operation time, and minimizing infection risks for hemodialysis patients. VenoStent aims to significantly impact the approximately 5 million vascular surgeries conducted annually, enhancing the quality and longevity of life for chronic kidney disease patients.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By leveraging advancements in bioengineering and nanotechnology, Nanopath provides granular and clinically actionable information that allows for the sensitive and specific detection of viral, bacterial, and fungal pathogens. This innovative approach eliminates the need for nucleic acid amplification, thereby transforming traditional testing methodologies. The company's goal is to deliver high-quality molecular testing results in minutes, ultimately improving health outcomes for women.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Selsym Biotech is a biotechnology company focused on developing innovative therapies for uncontrolled bleeding. Their primary product, Hemostatic Healing Hydrogels (H3), is designed to control bleeding in trauma and surgery situations. This therapy addresses critical issues such as platelet supply shortages and shelf life limitations, aiming to revolutionize hemorrhage control in emergency and surgical settings.

Lamassu Pharma is a biotech startup dedicated to addressing the critical unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown significant preclinical efficacy in mitigating mortality and morbidity associated with this condition. This therapeutic candidate was developed by leading scientists at Mayo Clinic and aims to improve medical outcomes for patients suffering from severe acute pancreatitis. Currently, Lamassu Pharma is engaged in safety testing of this compound in preparation for definitive clinical trials, with the ultimate goal of saving lives and enhancing the treatment landscape for this serious disease.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

RNAConnect specializes in developing enzymatic tools for visualizing and manipulating RNA, with a focus on low-abundance and long, structured RNAs. Their core product is a reverse transcriptase designed to provide greater visibility into these challenging RNA types and their various isoforms. This enzyme is optimized to synthesize cDNA with high fidelity and processivity, enabling researchers to study complex RNA template structures without the need for heat.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Endomimetics is a company focused on developing advanced bio-nanometric coating technology, particularly for stents aimed at enhancing care for patients affected by kidney diseases. The company's innovative coating mimics human tissue, which helps minimize the need for additional surgeries and improves the longevity of stents. By reducing complications associated with the presence of foreign materials in the body, Endomimetics aims to provide better medical solutions for kidney disease patients, ultimately leading to improved care and patient outcomes.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company offers a range of preclinical and toxicology services, utilizing advanced technologies such as quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans. L2P Research Labs also provides proprietary orthotopic and metastatic tumor models, enabling researchers to access a complete suite of research services tailored to their needs. Through its innovative approaches and state-of-the-art facilities, the company supports the advancement of scientific research in the fields of medicine and drug development.

RevBio is a biotechnology company focused on developing innovative solutions for bone repair. Its flagship product, Tetranite, is an injectable, self-setting, osteoconductive bone adhesive biomaterial designed to bond bone to bone and bone to metal in challenging environments. Tetranite is currently undergoing FDA review for various applications, including oral, craniofacial, orthopedic, and neurosurgical uses. This synthetic adhesive biodegrades over time, being replaced by new bone as part of the natural bone remodeling process, thus serving as a scaffold to promote bone growth. By utilizing this unique material, RevBio aims to reduce the duration and complexity of medical procedures, facilitate more minimally invasive surgeries, and enhance patient outcomes by decreasing pain, recovery time, and overall healthcare costs. The company is actively developing a portfolio of applications tailored for both dental and orthopedic fields.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to address herpes simplex virus-related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutics and prophylactic vaccine candidates aimed at reducing the spread of the virus and improving the management of symptoms associated with herpes infections. Through its research, Rational Vaccines aspires to revolutionize the treatment, prevention, and diagnosis of herpes and related conditions, ultimately enhancing the quality of life for individuals affected by these diseases.

AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative therapies for life-threatening diseases, particularly in the field of oncology. The company specializes in radiotherapies utilizing its alpha particle immunotherapy platform, which delivers radioisotopes through monoclonal antibodies to target and destroy cancer cells effectively. Its lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as an induction and conditioning agent for patients over 55 with relapsed or refractory acute myeloid leukemia prior to hematopoietic stem cell transplantation. Additionally, Actinium is developing Actimab-A, which is in Phase II trials for newly diagnosed AML patients aged 60 and older, as well as Actimab-M for penta-refractory multiple myeloma currently in Phase I trials. The company also collaborates with Astellas Pharma to advance its research initiatives. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in cancer treatment through its proprietary technologies.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Omniose is an early-stage biotechnology company focused on the development of next-generation conjugate vaccines aimed at combating infectious diseases. The company specializes in pneumococcal conjugate vaccines that leverage proprietary in vivo conjugating technology, allowing for broader protection against various bacterial strains. By utilizing bioconjugation technology, Omniose's approach circumvents reliance on synthetic chemistry techniques, thereby enhancing the efficiency of vaccine development. This innovative platform supports the creation of polysaccharide-protein conjugate-based vaccines targeting multiple respiratory pathogens, including Streptococcus pneumoniae, ultimately enabling healthcare professionals to provide more effective treatment options for patients.

Base Pair Biotechnologies, Inc. is a biotechnology company based in Pearland, Texas, specializing in the research, development, and discovery of aptamer affinity ligands. Established in 2012, the company offers custom aptamer development services and a catalog of ready-made aptamers. Its innovative platform incorporates novel libraries and proprietary methods for multiplexing the aptamer discovery process, allowing for efficient screening and validation. Base Pair Biotechnologies collaborates with academic, commercial, and government institutions to create advanced tools and technologies across various sectors, including diagnostics, therapeutics, animal testing, agriculture, and environmental testing. The company's expertise in aptamer research, which began in 2004, has positioned it as a leader in the field, enabling clients to obtain high-quality aptamers with reduced time and cost.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Burst Diagnostics is a company focused on advancing at-home and point-of-care testing through innovative diagnostic solutions. It has developed a rapid antigen diagnostics platform designed to deliver automated laboratory analysis in a user-friendly format. The company specializes in a paper-based testing system that enables immediate deployment from laboratory settings to home use. This system provides comparable sensitivity and specificity to traditional laboratory ELISA tests in an accessible format resembling a lateral flow assay. Burst Diagnostics aims to enhance the capabilities of medical communities, enabling efficient testing for various conditions, including SARS-CoV-2, among others.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients. By leveraging advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, the company aims to transform the traditional drug discovery process, which is often slow and prone to high failure rates. Greenstone Biosciences seeks to create a rapid and integrated computational platform that can efficiently deliver safe and effective therapeutics, addressing diseases with significant unmet medical needs. Through its innovative approach, the company is dedicated to improving patient outcomes and advancing therapeutic options.

Spinogenix, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing neurorestorative therapeutics for neurodegenerative and psychiatric diseases. Founded in 2016, the company aims to regenerate synapses in order to reverse declines in cognitive and motor functions associated with conditions such as brain injury and neurodegenerative disorders. Spinogenix's innovative approach involves creating a new class of therapeutics that can be used either as monotherapy or in combination with existing treatments, specifically targeting the degenerative processes unique to various diseases. The company's mission is to produce transformative therapeutics that address synaptic loss and dysfunction, ultimately enabling patients to restore critical brain connections and improve their overall quality of life.

Daxor Corporation is a medical device and biotechnology company based in New York, founded in 1970. It specializes in blood volume measurement, offering the BVA-100 Blood Volume Analyzer, the first FDA-approved instrument for the rapid and direct measurement of a patient's true blood volume. This device is utilized in diagnosing and managing various medical conditions, including congestive heart failure, critical care medicine, hypertension, and anemia. In addition to its core product, Daxor provides cryobanking services such as semen banking and blood storage, along with andrology and general laboratory testing services. The company also collaborates with the Uniformed Services University of the Health Sciences to research the effectiveness of its diagnostic tests in traumatic injury contexts. Daxor was previously known as Idant Corporation before rebranding in May 1973.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

Nexilico, Inc. is an early-stage biotechnology firm established in 2017 and headquartered in Albany, California. The company specializes in advancing microbiome and precision medicine through the development of innovative predictive computational platforms. These platforms enhance drug design and development, focusing on improving clinical outcomes in therapeutics. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge enables Nexilico to create novel microbiome-based approaches that support clients in optimizing drug development processes and outcomes.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Talus Bio is a biotechnology startup focused on drug discovery and development, particularly targeting challenging cancer transcription factors. The company employs an innovative approach that integrates functional proteomics, automated biology, and machine learning. Their MARMOT platform utilizes AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics. This platform is designed to advance drug development for gene regulation in oncology, aiming to create small-molecule therapies that can effectively control gene expression in cancer cells.

Morehouse School of Medicine, located in Atlanta, Georgia, is a distinguished institution focused on medical education, particularly for minority students. As a historically Black college and university (HBCU), it offers a range of degree programs, including medical degrees with specializations in fields such as Family Medicine, Internal Medicine, and Pediatrics, among others. In addition to its MD program, Morehouse provides master's degrees in Public Health and Biomedical Sciences, along with conducting significant research in areas like cardiovascular studies and health disparities. The institution emphasizes a commitment to diversity and offers scholarships to support disadvantaged students. The endowment fund managed by Morehouse School of Medicine plays a crucial role in funding scholarships, professorships, fellowships, and research initiatives, thereby enhancing its educational and public service missions.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

CivaTech Oncology is a medical device company based in Durham, North Carolina, that specializes in developing polymer-based devices for cancer treatment through localized low-dose-rate radiation. Founded in 2006, the company focuses on creating devices tailored for specific tumor types, leveraging its patented and patent-pending technology to enhance the effectiveness of brachytherapy. Its flagship product, the CivaString, has received FDA 510k clearance for the treatment of any solid tumor. CivaTech's innovations aim to improve treatment outcomes for early-stage cancers by significantly reducing procedure time, ensuring homogeneous dose distribution, and minimizing trauma to surrounding tissues.

Fesarius Therapeutics is a biotechnology company focused on developing and commercializing modified skin replacement products through innovative tissue engineering techniques. The company utilizes a proprietary method that incorporates microspheres within collagen hydrogels to optimize differential density interfaces, facilitating enhanced cell invasion into the scaffold. This approach aims to support the surgical repair of soft tissue defects and addresses a variety of medical needs, including advanced reconstruction, pelvic health, chronic wounds, and aesthetic applications. Fesarius Therapeutics is dedicated to providing cost-effective solutions that enable patients to heal from trauma, burns, or infections.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

iMetabolic Biopharma Corporation is an early-stage precision medicine company dedicated to developing innovative therapeutics for obesity-related diseases. Utilizing its proprietary iPlatform technology, the company aims to accelerate drug discovery and deliver affordable treatments to patients with high unmet medical needs.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Advent Therapeutics, based in Lumberville, Pennsylvania, is dedicated to developing therapies for micro-orphan applications, specifically targeting serious unmet medical needs in neonatal and pediatric populations. The company focuses on legacy drugs designed to address disorders in newborns, particularly those requiring intensive care in hospital settings. By providing specialized prenatal, neonatal, and pediatric medications, Advent Therapeutics aims to enhance the care pediatricians and healthcare professionals can offer to fragile patients, thereby improving health outcomes for these vulnerable groups.

Caeregen Therapeutics focuses on the development of innovative pharmacological therapies aimed at healing neurosensory diseases. The company specializes in regenerative medicine, creating treatments that repair, restore, and protect neurosensory tissues by leveraging biological pathways and signaling mechanisms associated with cellular and organ development. Through its research, Caeregen Therapeutics seeks to provide patients with potential solutions for conditions such as retinal-related vision loss, thereby addressing critical needs in the field of regenerative health.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Domus Diagnostics is a healthcare company based in Park City, Utah, founded in 2021. It specializes in providing a care diagnostics platform focused on respiratory disease home testing services. The company's devices are designed for everyday infectious disease testing and support governments and institutions in conducting large-scale testing during new infectious disease outbreaks. This approach aims to facilitate early treatment and prevent the spread of diseases, potentially mitigating pandemic-scale impacts.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

Sensor-Kinesis Corporation develops innovative medical devices focused on pathogen and virus detection. Founded in 2013 and based in Los Angeles, the company is advancing proprietary biosensor technology that integrates flexible micro biosensor chips with computer systems. These chips are designed to detect specific biomolecules and can be printed on various surfaces, enabling widespread application across multiple industries, including healthcare, food safety, and pharmaceuticals. By linking these sensors to smart devices, users can transmit and analyze biological signals in real time, facilitating improved health monitoring. Sensor-Kinesis aims to empower healthcare professionals and individuals with affordable, portable devices that provide enhanced detection capabilities for diseases and health-related risks, promoting better health outcomes and safety.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Vivani Medical is a preclinical-stage biopharmaceutical company focused on developing innovative medical solutions for chronic diseases and visual impairments. The company specializes in creating implantable visual prosthetics, including a retinal prosthesis designed to restore sight to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa. Utilizing its proprietary NanoPortal technology, Vivani Medical manufactures miniaturized, subdermal implants that facilitate long-term, consistent delivery of various medications. Through its commitment to research and development, Vivani Medical aims to enhance the quality of life for patients, enabling greater independence for those affected by vision loss and chronic conditions. Founded in 1998 and based in Sylmar, California, the company operates with two main divisions: Biopharm and Neuromodulation, focusing on innovative solutions in the medical field.

AivoCode Inc., established as a biotechnology company, specializes in innovative solutions for critical neurological disorders like traumatic brain injury and neurodegenerative diseases such as Alzheimer's. The company's proprietary technology revolves around unique peptides that selectively target molecular changes in affected brain regions, facilitating the delivery of various therapeutics and diagnostics. These peptides also exhibit intrinsic therapeutic properties. Notably, AivoCode's development has been solely funded through non-dilutive federal grants.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

The Indiana CTSI is dedicated to leveraging and strengthening the state’s life sciences community to achieve better health for people in Indiana.Leadership and staff at the Indiana CTSI are working to develop the best processes and resources to enable the efficient translation of scientific discoveries to patient care.Indiana CTSI programs and partnerships are designed to educate, attract and retain top research talent in the state for generations to come.

Chemeleon is a company that has developed an innovative platform technology for rapid and affordable diagnostics capable of detecting a wide array of analytes, including drugs, proteins, and viruses. Their proprietary in vitro diagnostic format delivers a colorimetric readout within minutes, visible to the naked eye, and does not require reagents, instruments, or specialized training. This decentralized testing approach empowers clinicians to extend point-of-care diagnostics and allows individuals to self-administer tests at the point of need. Chemeleon's diagnostics utilize highly selective molecular receptors combined with colorimetric nanomaterial reporters, facilitating immediate and actionable diagnoses that can significantly improve patient outcomes while reducing healthcare costs. Notably, the company developed a diagnostic for detecting beta-2-transferrin, a biomarker for Cerebrospinal Fluid leaks, resulting in substantial reductions in morbidity and healthcare expenses. With a focus on providing specificity and selectivity comparable to lab-based tests but in a fraction of the time and cost, Chemeleon's technology stands to transform healthcare accessibility, especially in resource-limited environments.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages groundbreaking research from the Akassoglou lab at Gladstone/UCSF, which identifies fibrin as a crucial factor in driving chronic innate immune activation associated with various diseases. By creating therapeutics that address neuroinflammation and vascular dysfunction, Therini Bio aims to provide potential treatments for conditions such as multiple sclerosis, thereby enhancing the quality of life for patients facing these challenging health issues.

Millennial Scientific is an advanced material and manufacturing company focused on Chromatography and allied products. Our chromatography product portfolio comprises the award-winning NanoPak-C all-carbon suite of products. They deliver high-performance extraction, separation, and purification of chemicals and biochemicals serving underserved or unserved Life- and Bio-Science market segments. These products are available as bulk stationary phase media or packed in solid-phase extraction (SPE) and liquid chromatography columns. NanoPak-C is attracting customers with analysis requirements outside the current silica-based column capabilities and seeking faster, more efficient analysis while reducing laboratory costs and solvent usage. It is benefiting customers seeking next-generation performance capabilities to separate structurally similar compounds, biologics, biobetters, or biosimilars.